Bindarit Attenuates Pain and Cancer-Related Inflammation by Influencing Myeloid Cells in a Model of Bone Cancer

  • Shenghou Liu
  • Hongwei Gao
  • Chunzheng Gao
  • Wenguang Liu
  • Deguo Xing
Original Article


C–C motif chemokine ligand 2 (CCL2) is a small cytokine that functions in inflammation and cancer development. Bindarit, a CCL2 inhibitor, is a small anti-inflammatory molecule proven safe by phase II trials in type 2 diabetic nephropathy patients. As cancer-related inflammation is a cause of pain, we investigated whether Bindarit suppresses cancer-related inflammation and pain. We established a bone-cancer mouse model by inoculating cancer cells. After applying Bindarit, we preformed pain sensitivity tests and checked cancer development by X-ray. Using flow cytometry and qRT-PCR assays, we assessed the effect of Bindarit on peripheral blood monocyte mobilization and M2 macrophage polarization. We also investigated the targets of Bindarit using western blotting and luciferase assay. Bindarit-treated mice performed better in pain sensitivity tests compare to control mice. X-ray imaging showed that Bindarit-treated mice had fewer cancer cell colonies and smaller overall tumor burden. Bindarit reduced the number of monocytes in peripheral blood and down-regulated the expression of M2 macrophage polarization makers. Bindarit also inhibited IKKβ phosphorylation. Bindarit efficiently relieves cancer-related pain and suppresses cancer development. Bindarit inhibits monocyte mobilization in peripheral blood as well as M2 macrophage polarization. IKKβ is identified as a target of Bindarit.


Bindarit CCL2 Cancer Inflammation Pain 



This work was supported by the Youth Fund of the Second Hospital of Shandong University (Y2013010049) and the Fund of Science and Technology Development Projects of Shandong Provence (No. 2012GSF11849).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Research involving human participants and/or animals

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.


  1. Baggiolini M, Dahinden CA (1994) CC chemokines in allergic inflammation. Immunol Today 15:127–133CrossRefPubMedGoogle Scholar
  2. Ble A, Mosca M, Di Loreto G et al (2011) Antiproteinuric effect of chemokine C–C motif ligand 2 inhibition in subjects with acute proliferative lupus nephritis. Am J Nephrol 34:367–372CrossRefPubMedGoogle Scholar
  3. Boekhoudt GH, Guo Z, Beresford GW et al (2003) Communication between NF-kappa B and Sp1 controls histone acetylation within the proximal promoter of the monocyte chemoattractant protein 1 gene. J Immunol 170:4139–4147CrossRefPubMedGoogle Scholar
  4. Caronni N, Savino B, Bonecchi R (2015) Myeloid cells in cancer-related inflammation. Immunobiology 220:249–253CrossRefPubMedGoogle Scholar
  5. Carr MW, Roth SJ, Luther E, Rose SS et al (1994) Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci USA 91:3652–3656CrossRefPubMedPubMedCentralGoogle Scholar
  6. Conductier G, Blondeau N, Guyon A et al (2010) The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases. J Neuroimmunol 224:93–100CrossRefPubMedGoogle Scholar
  7. Fabene PF, Bramanti P, Constantin G (2010) The emerging role for chemokines in epilepsy. J Neuroimmunol 224:22–27CrossRefPubMedGoogle Scholar
  8. Foresti ML, Arisi GM, Katki K et al (2009) Chemokine CCL2 and its receptor CCR2 are increased in the hippocampus following pilocarpine-induced status epilepticus. J Neuroinflammation 6:40CrossRefPubMedPubMedCentralGoogle Scholar
  9. Gerard C, Rollins BJ (2001) Chemokines and disease. Nat Immunol 2:108–115CrossRefPubMedGoogle Scholar
  10. Guglielmotti A, Silvestrini B, Saso L et al (1993) Chronic inflammatory response in the rat can be blocked by bindarit. Biochem Mol Biol Int 29:747–756PubMedGoogle Scholar
  11. Guglielmotti A, D’Onofrio E, Coletta I et al (2002) Amelioration of rat adjuvant arthritis by therapeutic treatment with bindarit, an inhibitor of MCP-1 and TNF-alpha production. Inflamm Res 51:252–258CrossRefPubMedGoogle Scholar
  12. Hickman SE, El Khoury J (2010) Mechanisms of mononuclear phagocyte recruitment in Alzheimer’s disease. CNS Neurol Disord Drug Targets 9:168–173CrossRefPubMedPubMedCentralGoogle Scholar
  13. Ialenti A et al (2011) Inhibition of in-stent stenosis by oral administration of bindarit in porcine coronary arteries. Arterioscler Thromb Vasc Biol 31:2448–2454CrossRefPubMedGoogle Scholar
  14. Kim JS, Gautam SC, Chopp M et al (1995) Expression of monocyte chemoattractant protein-1 and macrophage inflammatory protein-1 after focal cerebral ischemia in the rat. J Neuroimmunol 56:127–134CrossRefPubMedGoogle Scholar
  15. Lloyd CM, Dorf ME, Proudfoot A et al (1997) Role of MCP-1 and RANTES in inflammation and progression to fibrosis during murine crescentic nephritis. J Leukoc Biol 62:676–680CrossRefPubMedGoogle Scholar
  16. Lu Y, Jiang BC, Cao DL et al (2014) TRAF6 upregulation in spinal astrocytes maintains neuropathic pain by integrating TNF-alpha and IL-1beta signaling. Pain 155:2618–2629CrossRefPubMedPubMedCentralGoogle Scholar
  17. Luster AD, Rothenberg ME (1997) Role of the monocyte chemoattractant protein and eotaxin subfamily of chemokines in allergic inflammation. J Leukoc Biol 62:620–633CrossRefPubMedGoogle Scholar
  18. Mantovani A, Ming WJ, Balotta C et al (1986) Origin and regulation of tumor-associated macrophages: the role of tumor-derived chemotactic factor. Biochim Biophys Acta 865:59–67PubMedGoogle Scholar
  19. Mills CD, Lenz LL, Harris RA (2016) A breakthrough: macrophage-directed cancer immunotherapy. Cancer Res 76:513–516CrossRefPubMedPubMedCentralGoogle Scholar
  20. Mirolo M, Fabbri M, Sironi M et al (2008) Impact of the anti-inflammatory agent bindarit on the chemokinome: selective inhibition of the monocyte chemotactic proteins. Eur Cytokine Netw 19:119–122PubMedGoogle Scholar
  21. Mora E, Guglielmotti A, Biondi G et al (2012) Bindarit: an anti-inflammatory small molecule that modulates the NFkappaB pathway. Cell Cycle 11:159–169CrossRefPubMedPubMedCentralGoogle Scholar
  22. Ping D, Boekhoudt G, Zhang F et al (2000) Sp1 binding is critical for promoter assembly and activation of the MCP-1 gene by tumor necrosis factor. J Biol Chem 275:1708–1714CrossRefPubMedGoogle Scholar
  23. Qian BZ, Pollard JW (2010) Macrophage diversity enhances tumor progression and metastasis. Cell 141:39–51CrossRefPubMedPubMedCentralGoogle Scholar
  24. Ramnath RD, Ng SW, Guglielmotti A et al (2008) Role of MCP-1 in endotoxemia and sepsis. Int Immunopharmacol 8:810–818CrossRefPubMedGoogle Scholar
  25. Ransohoff RM, Hamilton TA, Tani M et al (1993) Astrocyte expression of mRNA encoding cytokines IP-10 and JE/MCP-1 in experimental autoimmune encephalomyelitis. FASEB J 7:592–600CrossRefPubMedGoogle Scholar
  26. Roca H, Varsos ZS, Pienta KJ (2009a) CCL2 is a negative regulator of AMP-activated protein kinase to sustain mTOR complex-1 activation, survivin expression, and cell survival in human prostate cancer PC3 cells. Neoplasia 11:1309–1317CrossRefPubMedPubMedCentralGoogle Scholar
  27. Roca H, Varsos ZS, Sud S et al (2009b) CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem 284:34342–34354CrossRefPubMedPubMedCentralGoogle Scholar
  28. Ruggenenti P, Perna A, Tonelli M et al (2010) Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial. Clin J Am Soc Nephrol 5:1928–1938CrossRefPubMedPubMedCentralGoogle Scholar
  29. Sanford DE, Belt BA, Panni RZ et al (2013) Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Clin Cancer Res 19:3404–3415CrossRefPubMedPubMedCentralGoogle Scholar
  30. Semple BD, Bye N, Rancan M et al (2010a) Role of CCL2 (MCP-1) in traumatic brain injury (TBI): evidence from severe TBI patients and CCL2−/− mice. J Cereb Blood Flow Metab 30:769–782CrossRefPubMedGoogle Scholar
  31. Semple BD, Kossmann T, Morganti-Kossmann MC (2010b) Role of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks. J Cereb Blood Flow Metab 30:459–473CrossRefPubMedGoogle Scholar
  32. Xia M, Sui Z (2009) Recent developments in CCR2 antagonists. Expert Opin Ther Pat 19:295–303CrossRefPubMedGoogle Scholar
  33. Xu LL, Warren MK, Rose WL et al (1996) Human recombinant monocyte chemotactic protein and other C-C chemokines bind and induce directional migration of dendritic cells in vitro. J Leukoc Biol 60:365–371CrossRefPubMedGoogle Scholar
  34. Zoja C, Corna D, Benedetti G et al (1998) Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease. Kidney Int 53:726–734CrossRefPubMedGoogle Scholar

Copyright information

© L. Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland 2017

Authors and Affiliations

  • Shenghou Liu
    • 1
  • Hongwei Gao
    • 2
  • Chunzheng Gao
    • 3
  • Wenguang Liu
    • 1
  • Deguo Xing
    • 2
  1. 1.Department of Joint SurgeryThe Second Hospital of Shandong UniversityJinanPeople’s Republic of China
  2. 2.Department of Trauma and OrthopedicsThe Second Hospital of Shandong UniversityJinanPeople’s Republic of China
  3. 3.Department of Spinal SurgeryThe Second Hospital of Shandong UniversityJinanPeople’s Republic of China

Personalised recommendations